The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A CRUK first-in-human phase I trial of a CDC7 Inhibitor, LY3143921 hydrate, in patients with advanced solid tumors.
 
Peter F. Gallagher
No Relationships to Disclose
 
Victoria Coyle
Research Funding - Almac Diagnostics; Bayer; Merck Sharp & Dohme; Sierra Oncology
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb; Eisai
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Eisai; Karus Therapeutics
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Eisai
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Lilly (Inst); Merck (Inst); Nutide (Inst); Ono Pharmaceutical (Inst); Roche (Inst); Sierra Oncology (Inst); Verastem (Inst); Vetex Medical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); Bristol-Myers Squibb; Pfizer (I); Roche/Genentech
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; MSD Oncology; Novartis; Octimet; Pierre Fabre; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Sally Clive
No Relationships to Disclose
 
Lesley McGuigan
No Relationships to Disclose
 
Patricia Roxburgh
Research Funding - AstraZeneca (Inst); Tesaro (Inst)
 
Noor Md Haris
No Relationships to Disclose
 
Stefan N. Symeonides
Consulting or Advisory Role - Agalimmune (Inst); Bicycle Therapeutics (Inst); Ellipses Pharma (Inst); EUSA Pharma (Inst); Novartis (Inst); OCTIMET (Inst); Vaccitech (Inst)
Research Funding - Boston Pharmaceuticals (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Sierra Oncology (Inst); Tioma Therapeutics (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ipsen; Ipsen
 
Gregory Naylor
No Relationships to Disclose
 
Saira Bashir
No Relationships to Disclose
 
Barbara Stanley
No Relationships to Disclose
 
Lisa Godfrey
No Relationships to Disclose
 
Moira Elliott
No Relationships to Disclose
 
Gavin Halbert
No Relationships to Disclose
 
Sue Brook
No Relationships to Disclose
 
Nicola Dobbs
No Relationships to Disclose
 
Richard H. Wilson
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; CV6 Therapeutics; Halozyme; Karus Therapeutics; Merck Serono; Pierre Fabre; Roche; Servier; Sirtex Medical
Research Funding - Almac Group (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono